125 related articles for article (PubMed ID: 31122816)
1. Is it possible NET-redifferentiation after chemotherapy?
Ergül N; Çermik TF; Dursun N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):31-34. PubMed ID: 31122816
[TBL] [Abstract][Full Text] [Related]
2. Malignant insulinoma: 18F-DOPA and 68Ga-DOTATATE PET/CT and treatment with 177Lu-DOTATATE.
Erhamamcı S; Sager S; Asa S; Uslu L; Akgun E; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):383-386. PubMed ID: 32487444
[No Abstract] [Full Text] [Related]
3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
5. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
6. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
10. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
11. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
12. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
14. Gastric Mucosal Hypertrophy Masquerading as Metastasis From Neuroendocrine Tumor of the Pancreas Detected on 68Ga-DOTANOC PET/CT.
Malik D; Elumalai R; Verma R; Belho ES; Seniaray N; Mahajan H
Clin Nucl Med; 2020 Jan; 45(1):74-75. PubMed ID: 31693612
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E
Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging.
Vija Racaru L; Sinigaglia M; Fontaine S; DʼAure D; Courbon F; Dierickx L
Clin Nucl Med; 2019 Jul; 44(7):e445-e448. PubMed ID: 31021912
[TBL] [Abstract][Full Text] [Related]
17. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N; Joubert-Zakeyh J; Pétorin C; Montoriol PF; Maqdasy S; Kelly A
Medicine (Baltimore); 2017 Feb; 96(6):e6062. PubMed ID: 28178157
[TBL] [Abstract][Full Text] [Related]
18. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
